金域醫學(603882.SH):控股股東及其一致行動人權益變動比例超過1%
格隆匯6月1日丨金域醫學(603882.SH)公佈,因公司於2023年2月10日實施股權激勵計劃行權導致總股本增加,持股比例被動稀釋,以及鑫鏝域、聖鉑域及鋭致於2023年1月30日至2023年5月31日期間通過集中競價方式減持公司無限售條件流通股496.77萬股,約佔當前公司總股本1.0631%,導致公司控股股東梁耀銘及其一致行動人嚴婷、曾湛文、鑫鏝域、聖鉑域、鋭致及聖域鈁合計持股比例累計減少超過1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.